Related Experiment Video
Updated: Dec 11, 2025
Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
Published on: April 4, 2022
Updates in Anti-anginal and Anti-ischemic Therapies for Acute Coronary Syndromes
Abhizith Deoker1, Angelica Lehker1, Debabrata Mukherjee2
1Department of Internal Medicine, Texas Tech University Health Sciences Center at El Paso, 4800 Alberta Avenue, El Paso, TX, 79905, USA.
Insights
This review covers anti-anginal and anti-ischemic therapies for acute coronary syndrome (ACS). Early diagnosis and evidence-based treatments, including long-term pharmacotherapy, improve patient outcomes.
Area of Science:
- Cardiology
- Internal Medicine
Background:
- Acute coronary syndrome (ACS) affects 1.5 million Americans annually.
- ACS is typically caused by atherosclerotic plaque rupture and coronary artery thrombosis.
- Effective management requires early diagnosis and targeted therapies.
Purpose of the Study:
- To review the current role of anti-anginal and anti-ischemic therapies in ACS management.
- To highlight recent advances in therapeutic strategies for acute coronary syndrome.
- To emphasize comprehensive patient care including risk reduction and medication adherence.
Main Methods:
- Review of contemporary anti-anginal and anti-ischemic therapies.
- Analysis of evidence-based treatment guidelines for acute coronary syndrome.
- Synthesis of recent findings in ACS pharmacotherapy and management.
Main Results:
- Early diagnosis and evidence-based therapies significantly improve clinical outcomes in ACS.
- Advances in anti-anginal and anti-ischemic treatments have been noted.
- Long-term pharmacotherapy recommendations include aspirin, beta-blockers, DAPT, statins, ACE inhibitors, and PCSK9 inhibitors.
Conclusions:
- Comprehensive management of ACS involves a team approach focusing on risk reduction and adherence.
- Long-term pharmacotherapy is crucial for secondary prevention in ACS patients.
- Continued research and application of evidence-based therapies are vital for improving ACS patient outcomes.
Purpose Of Review:
Acute coronary syndrome is a major health problem affecting ~ 1.5 million individuals a year in the USA. We review the contemporary role of anti-anginal and anti-ischemic therapies in the management of an individual presenting with an acute coronary syndrome.
Recent Findings:
Early diagnosis and appropriate evidence-based therapies significantly improve clinical outcomes in acute coronary syndrome patients. Typically, acute coronary syndrome is associated with rupture of an atherosclerotic plaque and either partial or complete thrombotic occlusion of a coronary artery. Management of an acute coronary syndrome is targeted towards this underlying pathophysiology. The last few years have seen significant advances in anti-anginal and anti-ischemic therapies in the management of patients with acute coronary syndrome. It is important to have a team effort to target risk reduction measures and to emphasize medication and dietary compliance. Long-term pharmacotherapy should include aspirin, beta-blocker, DAPT (for at least 1 year), statins, and ACE inhibitors and PCSK9 inhibitors if indicated.
More Related Videos
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
05:58Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
Published on: February 3, 2021
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:27Coronary Artery Disease V: Interprofessional Care
01:26Angina IV: Management
01:16Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:20Angina V: Nursing Management